Results 31 to 40 of about 133,774 (116)

Actinium-225 targeted alpha particle therapy for prostate cancer

Theranostics
Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment of prostate cancer (PCa). Actinium-225 (225Ac), a potent alpha-emitting radionuclide, may be incorporated into targeting vectors, causing robust and in some cases
A. Bidkar, Luann Zerefa, Surekha Yadav, H. VanBrocklin, R. Flavell   +4 more
semanticscholar   +1 more source

A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225

Pharmaceutics, 2020
Actinium-225 (225Ac) is receiving increased attention for its application in targeted radionuclide therapy, due to the short range of its emitted alpha particles in conjunction with their high linear energy transfer, which lead to the eradication of ...
Evangelia-Alexandra Salvanou, D. Stellas, C. Tsoukalas, Barbara Mavroidi, M. Paravatou‐Petsotas, N. Kalogeropoulos, S. Xanthopoulos, F. Denat, G. Laurent, R. Bazzi, S. Roux, P. Bouziotis   +11 more
semanticscholar   +1 more source

Actinium-225 in Targeted Alpha Therapy

Journal of Medical Physics
The utilization of actinium-225 (225Ac) radionuclides in targeted alpha therapy for cancer was initially outlined in 1993. Over the past two decades, substantial research has been conducted, encompassing the establishment of 225Ac production methods ...
A. Rahman, Mahathe Hasan Babu, Mustofa Khalid Ovi, M. Zilani, Israt Sultana Eithu, Amit Chakraborty   +5 more
semanticscholar   +1 more source

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma

Oncoimmunology, 2021
Multiple myeloma (MM) is a hematological malignancy characterized by the presence of clonal plasma cells in the bone marrow niche. Despite significant therapeutic advances, MM remains incurable for the majority of patients. Targeted radionuclide therapy (
K. De Veirman, J. Puttemans, A. Krasniqi, T. Ertveldt, Heleen Hanssens, Ema Romão, D. Hose, Cleo Goyvaert, P. Vlummens, S. Muyldermans, K. Breckpot, F. Bruchertseifer, A. Morgenstern, M. D'Huyvetter, N. Devoogdt   +14 more
semanticscholar   +1 more source

Control robusto H-infinito para la velocidad de desplazamiento de un UAV en base a estimación de flujo óptico

Revista Iberoamericana de Automática e Informática Industrial RIAI, 2021
Se presenta el diseño del control para la velocidad de desplazamiento de un vehículo aéreo de seis rotores. La técnica de diseño utilizada es el control óptimo en H–infinito con el objetivo de conseguir rendimiento robusto ante la incertidumbre en el ...
A.S. Ghersin, J.I. Giribet, J. Luiso, A. Tournour   +3 more
doaj   +1 more source

Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX

Chemical Science
Selective antibody targeted delivery of α particle emitting actinium-225 to tumors has significant therapeutic potential. This work highlights the design and synthesis of a new bifunctional macrocyclic diazacrown ether chelator, H2MacropaSqOEt, that can ...
Katherine A Morgan, C. Wichmann, Laura D Osellame, Zhipeng Cao, N. Guo, A. Scott, Paul S. Donnelly   +6 more
semanticscholar   +1 more source

Improving MACD Technical Analysis by Optimizing Parameters and Modifying Trading Rules: Evidence from the Japanese Nikkei 225 Futures Market

, 2021
Much research has examined performance or market efficiency by using the moving average convergence divergence (MACD) technical analysis tool. However, most tests fail to verify efficiency with the traditional parameter settings of 12, 26, and 9 days ...
Byung-Kook Kang
semanticscholar   +1 more source

In-House Preparation and Quality Control of Ac-225 Prostate-Specific Membrane Antigen-617 for the Targeted Alpha Therapy of Castration-Resistant Prostate Carcinoma

Indian Journal of Nuclear Medicine, 2021
Purpose: Ac-225 labeled with prostate-specific membrane antigen (PSMA-617), a transmembrane glycoprotein which is highly expressed in prostate carcinoma cells, is presently being considered a promising agent of targeted alpha therapy for the treatment of
Parul Thakral, J. Šimeček, Sebastian Marx, Jyotsna Kumari, Vineet Pant, I. Sen   +5 more
semanticscholar   +1 more source

Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.

Clinical Cancer Research
PURPOSE Initially, prostate cancer responds to hormone therapy but eventually resistance develops. Beta emitter-based PSMA (prostate-specific membrane antigen)-targeted radionuclide therapy is approved for the treatment of metastatic castration-resistant
Christoph A Schatz, S. Zitzmann-Kolbe, I. Moen, M. Klotz, Shankari Nair, Stefan Stargard, R. Bjerke, Katrine Wickstrøm Biseth, Y. Feng, Bård Indrevoll, V. Cruciani, Jenny Karlsson, B. Haendler, Carsten H Nielsen, M. Z. Alfsen, Stefanie Hammer, H. Hennekes, A. Cuthbertson, U. Hagemann, Aasmund Larsen   +19 more
semanticscholar   +1 more source

Supply and Clinical Application of Actinium-225 and Bismuth-213

Seminars in nuclear medicine, 2020
The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters 225Actinium and its daughter nuclide 213Bismuth ...
A. Morgenstern, C. Apostolidis, F. Bruchertseifer   +2 more
semanticscholar   +1 more source